{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:11:41Z","timestamp":1791515501649,"version":"4.3.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI093504"],"award-info":[{"award-number":["AI093504"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["CB10721"],"award-info":[{"award-number":["CB10721"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Botulinum neurotoxins (BoNTs) are highly potent, select agent toxins that inhibit neurotransmitter release at motor nerve terminals, causing muscle paralysis and death by asphyxiation. Other than post-exposure prophylaxis with antitoxin, the only treatment option for symptomatic botulism is intubation and supportive care until recovery, which can require weeks or longer. In previous studies, we reported the FDA-approved drug 3,4-diaminopyridine (3,4-DAP) reverses early botulism symptoms and prolongs survival in lethally intoxicated mice. However, the symptomatic benefits of 3,4-DAP are limited by its rapid clearance. Here we investigated whether 3,4-DAP could sustain symptomatic benefits throughout the full course of respiratory paralysis in lethally intoxicated rats. First, we confirmed serial injections of 3,4-DAP stabilized toxic signs and prolonged survival in rats challenged with 2.5 LD<jats:sub>50<\/jats:sub> BoNT\/A. Rebound of toxic signs and death occurred within hours after the final 3,4-DAP treatment, consistent with the short half-life of 3,4-DAP in rats. Based on these data, we next investigated whether the therapeutic benefits of 3,4-DAP could be sustained throughout the course of botulism\u00a0by\u00a0continuous infusion. To ensure administration of 3,4-DAP at clinically relevant doses, three infusion dose rates (0.5, 1.0 and 1.5\u00a0mg\/kg\u2219h) were identified that produced steady-state serum levels of 3,4-DAP consistent with clinical dosing. We then compared dose-dependent effects of 3,4-DAP on toxic signs and survival in rats intoxicated with 2.5 LD<jats:sub>50<\/jats:sub> BoNT\/A. In contrast to saline vehicle, which resulted in 100% mortality, infusion of 3,4-DAP at\u2009\u2265\u20091.0\u00a0mg\/kg\u2219h from 1 to 14 d after intoxication produced 94.4% survival and full resolution of toxic signs, without rebound of toxic signs after infusion was stopped. In contrast, withdrawal of 3,4-DAP infusion at 5 d resulted in re-emergence of toxic sign and death within 12\u00a0h, confirming antidotal outcomes require sustained 3,4-DAP treatment for longer than 5 d after intoxication. We exploited this novel survival model of lethal botulism to explore neurophysiological parameters of diaphragm paralysis and recovery. While neurotransmission was nearly eliminated at 5 d, neurotransmission was significantly improved at 21 d in 3,4-DAP-infused survivors, although still depressed compared to na\u00efve rats. 3,4-DAP is the first small molecule to reverse systemic paralysis and promote survival in animal models of botulism, thereby meeting a critical treatment need that is not addressed by post-exposure prophylaxis with conventional antitoxin. These data contribute to a growing body of evidence supporting the use of 3,4-DAP to treat clinical botulism.<\/jats:p>","DOI":"10.1186\/s10020-022-00487-4","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:25:29Z","timestamp":1654255529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine"],"prefix":"10.1186","volume":"28","author":[{"given":"James B.","family":"Machamer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin J.","family":"Vazquez-Cintron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean W.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle E.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber C.","family":"Altvater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen T.","family":"Pagarigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker B.","family":"Dubee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celinia A.","family":"Ondeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5703-4565","authenticated-orcid":false,"given":"Patrick M.","family":"McNutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"487_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0041-0101(00)00120-3","volume":"39","author":"M Adler","year":"2001","unstructured":"Adler M, Keller JE, Sheridan RE, Deshpande SS. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon off J Int Soc Toxinol. 2001;39:233\u201343.","journal-title":"Toxicon off J Int Soc Toxinol"},{"key":"487_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0022-510X(94)00225-D","volume":"129","author":"ML Aisen","year":"1995","unstructured":"Aisen ML, et al. 3,4-diaminopyridine as a treatment for amyotrophic lateral sclerosis. J Neurol Sci. 1995;129:21\u20134.","journal-title":"J Neurol Sci"},{"key":"487_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1124\/jpet.111.180653","volume":"338","author":"FH Al-Saleem","year":"2011","unstructured":"Al-Saleem FH, Nasser Z, Olson RM, Cao L, Simpson LL. Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare. J Pharmacol Exp Ther. 2011;338:503\u201317.","journal-title":"J Pharmacol Exp Ther"},{"key":"487_CR4","unstructured":"Amifampridine Drug Approval Package. U.S. Food and Drug Administration website. In."},{"key":"487_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224700","volume":"14","author":"DM Anderson","year":"2019","unstructured":"Anderson DM, et al. Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent product. PLoS ONE. 2019;14: e0224700.","journal-title":"PLoS ONE"},{"key":"487_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1056\/NEJMoa051926","volume":"354","author":"SS Arnon","year":"2006","unstructured":"Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354:462\u201371.","journal-title":"N Engl J Med"},{"key":"487_CR7","doi-asserted-by":"publisher","first-page":"8122","DOI":"10.1016\/S0021-9258(17)37168-5","volume":"269","author":"F Bartels","year":"1994","unstructured":"Bartels F, et al. Specific antibodies against the Zn(2+)-binding domain of clostridial neurotoxins restore exocytosis in chromaffin cells treated with tetanus or botulinum A neurotoxin. J Biol Chem. 1994;269:8122\u20137.","journal-title":"J Biol Chem"},{"key":"487_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/toxsci\/kfv254","volume":"149","author":"PH Beske","year":"2016","unstructured":"Beske PH, et al. Botulinum and tetanus neurotoxin-induced blockade of synaptic transmission in networked cultures of human and rodent neurons. Toxicol Sci. 2016;149:503\u201315.","journal-title":"Toxicol Sci"},{"key":"487_CR9","doi-asserted-by":"publisher","first-page":"15862","DOI":"10.1038\/s41598-017-16064-3","volume":"7","author":"PH Beske","year":"2017","unstructured":"Beske PH, Hoffman KM, Machamer JB, Eisen MR, McNutt PM. Use-dependent potentiation of voltage-gated calcium channels rescues neurotransmission in nerve terminals intoxicated by botulinum neurotoxin serotype A. Sci Rep. 2017;7:15862.","journal-title":"Sci Rep"},{"key":"487_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.toxicon.2017.10.017","volume":"147","author":"PH Beske","year":"2018","unstructured":"Beske PH, Bradford AB, Hoffman KM, Mason SJ, McNutt PM. In vitro and ex vivo screening of candidate therapeutics to restore neurotransmission in nerve terminals intoxicated by botulinum neurotoxin serotype A1. Toxicon off J Int Soc Toxinol. 2018;147:47\u201353.","journal-title":"Toxicon off J Int Soc Toxinol"},{"key":"487_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.taap.2018.01.012","volume":"341","author":"AB Bradford","year":"2018","unstructured":"Bradford AB, Machamer JB, Russo TM, McNutt PM. 3,4-diaminopyridine reverses paralysis in botulinum neurotoxin-intoxicated diaphragms through two functionally distinct mechanisms. Toxicol Appl Pharmacol. 2018;341:77\u201386.","journal-title":"Toxicol Appl Pharmacol"},{"key":"487_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/NRL.0b013e31816f2cdd","volume":"14","author":"A Brashear","year":"2008","unstructured":"Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist. 2008;14:289\u201398.","journal-title":"Neurologist"},{"key":"487_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nature03123","volume":"432","author":"MA Breidenbach","year":"2004","unstructured":"Breidenbach MA, Brunger AT. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature. 2004;432:925\u20139.","journal-title":"Nature"},{"key":"487_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1113\/jphysiol.1949.sp004364","volume":"109","author":"AS Burgen","year":"1949","unstructured":"Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109:10\u201324.","journal-title":"J Physiol"},{"key":"487_CR15","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.1523\/JNEUROSCI.17-19-07190.1997","volume":"17","author":"M Capogna","year":"1997","unstructured":"Capogna M, McKinney RA, O\u2019Connor V, Gahwiler BH, Thompson SM. Ca2+ or Sr2+ partially rescues synaptic transmission in hippocampal cultures treated with botulinum toxin A and C, but not tetanus toxin. J Neurosci. 1997;17:7190\u2013202.","journal-title":"J Neurosci"},{"key":"487_CR16","unstructured":"Centers for Disease Control and Prevention. Possession, Use, and Transfer of Select Agents and Toxins; Biennial Review of the List of Select Agents and Toxins and Enhanced Biosafety Requirements. Final rule. Fed Regist. 2017; pp. 6278\u20136294."},{"key":"487_CR17","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1016\/S0021-9258(17)39364-X","volume":"260","author":"LJ Cruz","year":"1985","unstructured":"Cruz LJ, et al. Conus geographus toxins that discriminate between neuronal and muscle sodium channels. J Biol Chem. 1985;260:9280\u20138.","journal-title":"J Biol Chem"},{"key":"487_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/DMP.0b013e318158c5fd","volume":"1","author":"ZF Dembek","year":"2007","unstructured":"Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep. 2007;1:122\u201334.","journal-title":"Disaster Med Public Health Prep"},{"key":"487_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1113\/jphysiol.1987.sp016546","volume":"386","author":"JO Dolly","year":"1987","unstructured":"Dolly JO, Lande S, Wray DW. The effects of in vitro application of purified botulinum neurotoxin at mouse motor nerve terminals. J Physiol. 1987;386:475\u201384.","journal-title":"J Physiol"},{"key":"487_CR20","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1083\/jcb.200305098","volume":"162","author":"M Dong","year":"2003","unstructured":"Dong M, et al. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol. 2003;162:1293\u2013303.","journal-title":"J Cell Biol"},{"key":"487_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1123654","volume":"312","author":"M Dong","year":"2006","unstructured":"Dong M, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006;312:592\u20136.","journal-title":"Science"},{"key":"487_CR22","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.2174\/1568026616666160413135630","volume":"16","author":"AJ Duplantier","year":"2016","unstructured":"Duplantier AJ, Kane CD, Bavari S. Searching for therapeutics against botulinum neurotoxins: a true challenge for drug discovery. Curr Top Med Chem. 2016;16:2330\u201349.","journal-title":"Curr Top Med Chem"},{"key":"487_CR23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/mus.20751","volume":"35","author":"LG Ermilov","year":"2007","unstructured":"Ermilov LG, Mantilla CB, Rowley KL, Sieck GC. Safety factor for neuromuscular transmission at type-identified diaphragm fibers. Muscle Nerve. 2007;35:800\u20133.","journal-title":"Muscle Nerve"},{"key":"487_CR24","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1073\/pnas.0611213104","volume":"104","author":"LM Eubanks","year":"2007","unstructured":"Eubanks LM, et al. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci USA. 2007;104:2602\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"487_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0149-7634(05)80101-0","volume":"15","author":"PI Feder","year":"1991","unstructured":"Feder PI, Hobson DW, Olson CT, Joiner RL, Matthews MC. Stagewise, adaptive dose allocation for quantal response dose\u2013response studies. Neurosci Biobehav Rev. 1991;15:109\u201314.","journal-title":"Neurosci Biobehav Rev"},{"key":"487_CR26","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1074\/jbc.M209821200","volume":"278","author":"PG Foran","year":"2003","unstructured":"Foran PG, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 2003;278:1363\u201371.","journal-title":"J Biol Chem"},{"key":"487_CR27","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/01.anes.0000267597.65120.16","volume":"106","author":"CG Frick","year":"2007","unstructured":"Frick CG, et al. Long-term effects of botulinum toxin on neuromuscular function. Anesthesiology. 2007;106:1139\u201346.","journal-title":"Anesthesiology"},{"key":"487_CR28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1152\/jn.00705.2015","volume":"119","author":"MGZ Ghali","year":"2018","unstructured":"Ghali MGZ. Phrenic motoneurons: output elements of a highly organized intraspinal network. J Neurophysiol. 2018;119:1057\u201370.","journal-title":"J Neurophysiol"},{"key":"487_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1086\/518890","volume":"45","author":"SL Gottlieb","year":"2007","unstructured":"Gottlieb SL, et al. Long-term outcomes of 217 botulism cases in the Republic of Georgia. Clin Infect Dis. 2007;45:174\u201380.","journal-title":"Clin Infect Dis"},{"key":"487_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0092-8674(00)80512-7","volume":"90","author":"PI Hanson","year":"1997","unstructured":"Hanson PI, Roth R, Morisaki H, Jahn R, Heuser JE. Structure and conformational changes in NSF and its membrane receptor complexes visualized by quick-freeze\/deep-etch electron microscopy. Cell. 1997;90:523\u201335.","journal-title":"Cell"},{"key":"487_CR31","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1002\/j.1460-2075.1994.tb06834.x","volume":"13","author":"T Hayashi","year":"1994","unstructured":"Hayashi T, et al. Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly. EMBO J. 1994;13:5051\u201361.","journal-title":"EMBO J"},{"key":"487_CR32","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/bdd.2203","volume":"40","author":"N Ishida","year":"2019","unstructured":"Ishida N, et al. Pharmacokinetics and tissue distribution of 3,4-diaminopyridine in rats. Biopharm Drug Dispos. 2019;40:294.","journal-title":"Biopharm Drug Dispos"},{"key":"487_CR33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.neuron.2017.02.047","volume":"94","author":"SL Jackman","year":"2017","unstructured":"Jackman SL, Regehr WG. The mechanisms and functions of synaptic facilitation. Neuron. 2017;94:447\u201364.","journal-title":"Neuron"},{"issue":"1679\u20131686","key":"487_CR34","volume":"25","author":"R Khounlo","year":"2017","unstructured":"Khounlo R, Kim J, Yin L, Shin YK. Botulinum toxins A and E inflict dynamic destabilization on t-SNARE to impair SNARE assembly and membrane fusion. Structure. 2017;25(1679\u20131686): e1675.","journal-title":"Structure"},{"key":"487_CR35","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1113\/jphysiol.1984.sp015484","volume":"356","author":"YI Kim","year":"1984","unstructured":"Kim YI, Lomo T, Lupa MT, Thesleff S. Miniature end-plate potentials in rat skeletal muscle poisoned with botulinum toxin. J Physiol. 1984;356:587\u201399.","journal-title":"J Physiol"},{"key":"487_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0006-3495(78)85503-9","volume":"22","author":"GE Kirsch","year":"1978","unstructured":"Kirsch GE, Narahashi T. 3,4-diaminopyridine. A potent new potassium channel blocker. Biophys J. 1978;22:507\u201312.","journal-title":"Biophys J"},{"key":"487_CR37","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1113\/jphysiol.1976.sp011610","volume":"262","author":"ME Kriebel","year":"1976","unstructured":"Kriebel ME, Llados F, Matteson DR. Spontaneous subminature end-plate potentials in mouse diaphragm muscle: evidence for synchronous release. J Physiol. 1976;262:553\u201381.","journal-title":"J Physiol"},{"key":"487_CR38","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.bbapap.2014.02.012","volume":"1844","author":"R Kumar","year":"2014","unstructured":"Kumar R, Kukreja RV, Cai S, Singh BR. Differential role of molten globule and protein folding in distinguishing unique features of botulinum neurotoxin. Biochim Biophys Acta. 2014;1844:1145\u201352.","journal-title":"Biochim Biophys Acta"},{"key":"487_CR39","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1152\/jn.00168.2017","volume":"119","author":"R Laghaei","year":"2018","unstructured":"Laghaei R, et al. Transmitter release site organization can predict synaptic function at the neuromuscular junction. J Neurophysiol. 2018;119:1340\u201355.","journal-title":"J Neurophysiol"},{"key":"487_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/molecules16010202","volume":"16","author":"B Li","year":"2010","unstructured":"Li B, et al. Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules. 2010;16:202\u201320.","journal-title":"Molecules"},{"key":"487_CR41","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1128\/CMR.19.2.298-314.2006","volume":"19","author":"M Lindstrom","year":"2006","unstructured":"Lindstrom M, Korkeala H. Laboratory diagnostics of botulism. Clin Microbiol Rev. 2006;19:298\u2013314.","journal-title":"Clin Microbiol Rev"},{"key":"487_CR42","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.1065","volume":"3","author":"B Lu","year":"2015","unstructured":"Lu B. The destructive effect of botulinum neurotoxins on the SNARE protein: SNAP-25 and synaptic membrane fusion. PeerJ. 2015;3: e1065.","journal-title":"PeerJ"},{"key":"487_CR43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.physbeh.2009.09.005","volume":"98","author":"A Luttjohann","year":"2009","unstructured":"Luttjohann A, Fabene PF, van Luijtelaar G. A revised Racine\u2019s scale for PTZ-induced seizures in rats. Physiol Behav. 2009;98:579\u201386.","journal-title":"Physiol Behav"},{"key":"487_CR44","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1152\/jn.00292.2012","volume":"108","author":"V Marchenko","year":"2012","unstructured":"Marchenko V, Ghali MG, Rogers RF. Motoneuron firing patterns underlying fast oscillations in phrenic nerve discharge in the rat. J Neurophysiol. 2012;108:2134\u201343.","journal-title":"J Neurophysiol"},{"key":"487_CR45","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1021\/cb1002366","volume":"5","author":"AV Mayorov","year":"2010","unstructured":"Mayorov AV, et al. Symptomatic relief of botulinum neurotoxin\/a intoxication with aminopyridines: a new twist on an old molecule. ACS Chem Biol. 2010;5:1183\u201391.","journal-title":"ACS Chem Biol"},{"key":"487_CR46","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"KM McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321:1567\u201371.","journal-title":"N Engl J Med"},{"key":"487_CR47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1113\/jphysiol.1981.sp013586","volume":"311","author":"EM McLachlan","year":"1981","unstructured":"McLachlan EM, Martin AR. Non-linear summation of end-plate potentials in the frog and mouse. J Physiol. 1981;311:307\u201324.","journal-title":"J Physiol"},{"key":"487_CR48","doi-asserted-by":"crossref","unstructured":"McNutt PM et al. Neuronal delivery of antibodies has therapeutic effects in animal models of botulism. Sci Transl Med. 2021;13.","DOI":"10.1126\/scitranslmed.abd7789"},{"key":"487_CR49","doi-asserted-by":"crossref","unstructured":"Miyashita SI, Zhang J, Zhang S, Shoemaker CB, Dong M. Delivery of single-domain antibodies into neurons using a chimeric toxin-based platform is therapeutic in mouse models of botulism. Sci Transl Med. 2021;13.","DOI":"10.1126\/scitranslmed.aaz4197"},{"key":"487_CR50","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.toxicon.2008.11.018","volume":"54","author":"M Montal","year":"2009","unstructured":"Montal M. Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel. Toxicon off J Int Soc Toxinol. 2009;54:565\u20139.","journal-title":"Toxicon off J Int Soc Toxinol"},{"key":"487_CR51","unstructured":"National Botulism Surveillance Annual Summaries [Internet]. Available from: http:\/\/www.cdc.gov\/nationalsurveillance\/botulism-surveillance.html. 2022a"},{"key":"487_CR52","unstructured":"National Botulism Surveillance, Annual Summaries [Internet]. Available from: http:\/\/www.cdc.gov\/nationalsurveillance\/botulism-surveillance.html. 2022b."},{"key":"487_CR53","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/mus.25208","volume":"55","author":"F Ng","year":"2017","unstructured":"Ng F, et al. Effect of 3,4-diaminopyridine at the murine neuromuscular junction. Muscle Nerve. 2017;55:223\u201331.","journal-title":"Muscle Nerve"},{"key":"487_CR54","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1093\/cid\/cix815","volume":"66","author":"JC O'Horo","year":"2017","unstructured":"O\u2019Horo JC, et al. Efficacy of antitoxin therapy in treating patients with foodborne botulism: a systematic review and meta-analysis of cases, 1923\u20132016. Clin Infect Dis. 2017;66:S43\u201356.","journal-title":"Clin Infect Dis"},{"key":"487_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100302","volume":"296","author":"KS Ojala","year":"2021","unstructured":"Ojala KS, et al. A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs. J Biol Chem. 2021;296: 100302.","journal-title":"J Biol Chem"},{"key":"487_CR56","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/17460441.2017.1303476","volume":"12","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini M, Rossetto O. Challenges in searching for therapeutics against Botulinum Neurotoxins. Expert Opin Drug Discov. 2017;12:497\u2013510.","journal-title":"Expert Opin Drug Discov"},{"key":"487_CR57","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1124\/pr.116.012658","volume":"69","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69:200\u201335.","journal-title":"Pharmacol Rev"},{"key":"487_CR58","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/1799","volume":"5","author":"MA Poirier","year":"1998","unstructured":"Poirier MA, et al. The synaptic SNARE complex is a parallel four-stranded helical bundle. Nat Struct Biol. 1998;5:765\u20139.","journal-title":"Nat Struct Biol"},{"key":"487_CR59","doi-asserted-by":"crossref","unstructured":"Richardson JS et al. Safety and clinical outcomes of an equine-derived heptavalent botulinum antitoxin treatment for confirmed or suspected botulism in the United States. Clin Infect Dis. 2019.","DOI":"10.1093\/cid\/ciz515"},{"key":"487_CR60","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.170.3958.648","volume":"170","author":"S Rotshenker","year":"1970","unstructured":"Rotshenker S, Rahamimoff R. Neuromuscular synapse: stochastic properties of spontaneous release of transmitter. Science. 1970;170:648\u20139.","journal-title":"Science"},{"key":"487_CR61","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1523\/JNEUROSCI.4663-10.2011","volume":"31","author":"R Ruiz","year":"2011","unstructured":"Ruiz R, et al. Active zones and the readily releasable pool of synaptic vesicles at the neuromuscular junction of the mouse. J Neurosci. 2011;31:2000\u20138.","journal-title":"J Neurosci"},{"key":"487_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0041-008X(86)90133-X","volume":"84","author":"LS Siegel","year":"1986","unstructured":"Siegel LS, Johnson-Winegar AD, Sellin LC. Effect of 3,4-diaminopyridine on the survival of mice injected with botulinum neurotoxin type A, B, E, or F. Toxicol Appl Pharmacol. 1986;84:255\u201363.","journal-title":"Toxicol Appl Pharmacol"},{"key":"487_CR63","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.chembiol.2007.03.014","volume":"14","author":"NR Silvaggi","year":"2007","unstructured":"Silvaggi NR, et al. Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol. 2007;14:533\u201342.","journal-title":"Chem Biol"},{"key":"487_CR64","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev.pharmtox.44.101802.121554","volume":"44","author":"LL Simpson","year":"2004","unstructured":"Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44:167\u201393.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"487_CR65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.toxicon.2013.02.014","volume":"68","author":"L Simpson","year":"2013","unstructured":"Simpson L. The life history of a botulinum toxin molecule. Toxicon off J Int Soc Toxinol. 2013;68:40\u201359.","journal-title":"Toxicon off J Int Soc Toxinol"},{"key":"487_CR66","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1086\/444507","volume":"41","author":"J Sobel","year":"2005","unstructured":"Sobel J. Botulism. Clin Infect Dis. 2005;41:1167\u201373.","journal-title":"Clin Infect Dis"},{"key":"487_CR67","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000336354","volume":"38","author":"N Souayah","year":"2012","unstructured":"Souayah N, et al. Trends in outcome and hospitalization charges of adult patients admitted with botulism in the United States. Neuroepidemiology. 2012;38:233\u20136.","journal-title":"Neuroepidemiology"},{"key":"487_CR68","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/26412","volume":"395","author":"RB Sutton","year":"1998","unstructured":"Sutton RB, Fasshauer D, Jahn R, Brunger AT. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature. 1998;395:347\u201353.","journal-title":"Nature"},{"key":"487_CR69","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.tins.2012.09.009","volume":"36","author":"TB Tarr","year":"2013","unstructured":"Tarr TB, Dittrich M, Meriney SD. Are unreliable release mechanisms conserved from NMJ to CNS? Trends Neurosci. 2013;36:14\u201322.","journal-title":"Trends Neurosci"},{"key":"487_CR70","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/psp4.12218","volume":"6","author":"N Thakkar","year":"2017","unstructured":"Thakkar N, et al. Population pharmacokinetics\/pharmacodynamics of 3,4-diaminopyridine free base in patients with Lambert-Eaton Myasthenia. CPT Pharmacometr Syst Pharmacol. 2017;6:625\u201334.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"487_CR71","first-page":"260","volume":"227","author":"RH Thomsen","year":"1983","unstructured":"Thomsen RH, Wilson DF. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther. 1983;227:260\u20135.","journal-title":"J Pharmacol Exp Ther"},{"key":"487_CR72","doi-asserted-by":"crossref","unstructured":"Vazquez-Cintron E et al. Symptomatic treatment of botulism with a clinically approved small molecule. JCI Insight 2020;5.","DOI":"10.1172\/jci.insight.132891"},{"key":"487_CR73","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1378\/chest.98.3.620","volume":"98","author":"PG Wilcox","year":"1990","unstructured":"Wilcox PG, Morrison NJ, Pardy RL. Recovery of the ventilatory and upper airway muscles and exercise performance after type A botulism. Chest. 1990;98:620\u20136.","journal-title":"Chest"},{"key":"487_CR74","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0301-0082(00)00055-1","volume":"64","author":"SJ Wood","year":"2001","unstructured":"Wood SJ, Slater CR. Safety factor at the neuromuscular junction. Prog Neurobiol. 2001;64:393\u2013429.","journal-title":"Prog Neurobiol"},{"key":"487_CR75","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1093\/cid\/cix816","volume":"66","author":"PA Yu","year":"2017","unstructured":"Yu PA, et al. Safety and improved clinical outcomes in patients treated with new equine-derived heptavalent botulinum antitoxin. Clin Infect Dis. 2017;66:S57\u201364.","journal-title":"Clin Infect Dis"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-022-00487-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-022-00487-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-022-00487-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T13:22:41Z","timestamp":1654262561000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-022-00487-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["487"],"URL":"https:\/\/doi.org\/10.1186\/s10020-022-00487-4","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"19 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was approved by the Animal Care and Use Committee at the United States Army Medical Research Institute of Chemical Defense (USAMRICD) and conducted according to the principles stated in the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966. The views expressed in this manuscript are those of the author(s) and do not reflect the official policy of the Department of Army, Department of Defense, National Institutes of Health or the U.S. Government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}